Methods and principles in medicinal chemistry, v. 6.
CONTENTS NOTE
Text of Note
Rational Design of Bioactive Molecules Examples of Active Areas of Structure-Based Design From Renin to HIV-1 Protease Zinc Endoproteases: A Structural Superfamily Structure-Based Design of Potent Beta-Lactamase Inhibitors Inhibition of Sialidase Rational Design of Inhibitors of HIV-1 Reverse Transcriptase New Computational Approaches to Predict Protein-Ligand Interactions The Future of Structure-Based Design: A Worthy Precept?
SUMMARY OR ABSTRACT
Text of Note
Most drugs bind to a clearly defined macromolecular target that is complementary in terms of structure and chemistry. This observation is the basic paradigm of structure-based ligand design. Although this method first emerged in the 1980s, it has already become a powerful tool for pharmaceutical research. Much has been learned, however, since the first attempts to discover drugs on the basis of available biochemical and structural data. Nowadays, structure-based ligand design is an established method for creating drugs with new structural features, for modifying binding activities and pharmaco.